To view the October 2019 edition of eNews please click here.
Louvain la Neuve, Belgium, 1st October 2019 / Sciad Newswire / N-SIDE, provider of innovative software and strategic consulting services, announced that AstraZeneca has signed an agreement to implement the N-SIDE Suite for Clinical Trials. Within the scope of this agreement, AstraZeneca will use specifically the N-SIDE Supply and Dashboard Apps in order to design, plan and monitor their clinical trial supply chain.
John Murray, Supply Chain Transformation Lead at AstraZeneca, commented: “N-SIDE’s Suite provides a tremendous opportunity for AstraZeneca to collaborate across key areas of…
Cambridge, UK, 30 September 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes.
Martin Bertschinger…
Today, Stevenage Bioscience Catalyst (SBC) has announced the appointment of two new Non-Executive Directors (NEDs) to its Board. Clare Terlouw, Head of Corporate Development at Syncona Investment Management Limited and Jon Green, Chair of One Nucleus, will be joining the SBC Board on 1st October 2019.
Clare is Head of Corporate Development at Syncona Investment Management Limited and has 15 years’ experience as a specialist healthcare and life sciences corporate financier in London. She joined Syncona from Numis Securities, where she was a Managing Director, Healthcare & Life Sciences,…
Cambridge, UK; September 27, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, will present a poster today that details an expanding body of evidence for the dual mechanism-of-action of the company’s anti-ICOS program, KY1044. The poster will be presented at the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CICON), being held at the Espace Grande Arche in Paris September 25-28, 2019.
KY1044 is a novel fully-human antibody that binds ICOS and is designed to both deplete intratumoral regulatory T cells and stimulate…
AMSBIO has introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.Targeted cancer therapy represents a promising new cancer treatment, one which delivers drugs in specific carriers and interferes with the specific target molecules that play a critical role in tumour growth and progression. Exosomes expressing specific surface markers (among them CD81, CD63, and CD9) have been found to play roles in cancer progression and tumorigenesis as a transporter of miRNA. As a delivery system, they can therefore potentially be…
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Royston, UK – Sept. 24, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has joined UK Medicines Discovery Catapult’s Discovery Services Platform, partnering with other best-in-class service providers to help improve preclinical drug discovery success rates.
From its GLP-accredited UK facility, BioIVT’s PHASEZERO® Research Services team will provide specialist support for generating human tissue-based…
Harpenden, UK, 24 September 2019: St George Street Capital (SGSC), a UK registered charity, has signed a license agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
The two compounds to be developed are part of AstraZeneca’s Emerging Innovation Unit, which explores drug re-purposing for novel indications by working with academic institutions through its Open Innovation programme (www.openinnovation.astrazeneca.com). The…
Aston Particle Technologies (APT) has significantly expanded its in-house R&D capabilities by investing in two benchtop systems – designed by Ely-based GB Innomech (Innomech) – to prepare small quantities of blended pharmaceutical powders for use in its formulation development projects for pharmaceutical companies.
APT is already working with a number of large multinational pharmaceutical companies but the two new systems will allow it to further increase its commercialisation activities and the number and scale of development projects it can work on simultaneously. The new systems could…
Global Regulatory Services (GRS) spins out new Irish Consultancy, Med-Di-Dia, to focus on EU MedTech
GRS spins out new Irish Consultancy, Med-Di-Dia (www.med-di-dia.com), to focus on EU MedTech regulations and quality compliance requirements. The official launch was held in Galway on Monday 16th September 2019. We were delighted to welcome the Mayor of Galway, Councillor Mike Cubbard, who started our celebrations with a thoughtful and supportive speech. And talking about ‘support’, we’ve had such a warm welcome by the Galway Technology Centre (where the new office is), Galway City and Ireland as a whole. Everyone has been so helpful. It just goes to show how collaboration really works…